Law / Business

Add as a preferred source on Google

German Court Overturns Injunction Blocking Merck’s Keytruda SC Sales

Halozyme plans a new German infringement lawsuit. A separate Dutch ruling imposed restrictions in eight markets, subject to conditions involving certain foreign patent rights.

Updated 1 min read
Merck’s headquarters campus stands beneath an overcast sky in Darmstadt, Germany / EconoTimes.ai
Merck’s headquarters campus stands beneath an overcast sky in Darmstadt, Germany / EconoTimes.ai

Halozyme Therapeutics Inc. said Germany’s Higher Regional Court overturned an injunction against Merck’s Keytruda SC, removing that German sales restriction as a separate patent dispute continues across Europe.

Halozyme said Nov. 19 that it disagrees with the decision and intends to bring a new German case seeking a lasting remedy. The injunction, issued in December 2025, had barred Merck from offering and distributing Keytruda SC in Germany. Merck’s November filing with the U.S. Securities and Exchange Commission said it had appealed and that the hearing was scheduled for Nov. 19, 2026.

The dispute concerns Halozyme’s European Patent No. 2,797,622, part of its modified hyaluronidase (MDASE) portfolio. In a separate case, the District Court of The Hague found infringement in a judgment dated Oct. 7, 2026, and ordered restrictions involving the Netherlands, Belgium, Denmark, France, Ireland, Italy, Sweden and Switzerland. The judgment makes those restrictions subject to conditions for certain foreign patent rights.

Merck’s filing also said it had brought actions seeking to revoke the European patent in several jurisdictions, including Germany. Halozyme said its MDASE patents are separate from its ENHANZE licensing program and that the German result would not affect ENHANZE licensees or related revenue.

Halozyme’s planned lawsuit is the next stated step in the German dispute; the filing itself has not been confirmed.

Related articles

View all